Related Experiment Video

Updated: Jul 12, 2026

Selective Harvesting of Marginating-hepatic Leukocytes
06:53

Selective Harvesting of Marginating-hepatic Leukocytes

Published on: July 21, 2016

6.1K

Reduction in peripheral blood K cells and activated T cells in primary biliary cirrhosis

G P Sandilands, R N Macsween, K G Gray

    Gut
    |December 1, 1977
    PubMed

    Insights

    Primary biliary cirrhosis (PBC) patients show reduced activated T cells and K cells, impacting immune function. This contrasts with chronic active hepatitis (CAH), indicating specific immune alterations in PBC.

    Area of Science:

    • Immunology
    • Hepatology

    Background:

    • Primary biliary cirrhosis (PBC) and chronic active hepatitis (CAH) are distinct liver diseases with complex immune system involvement.
    • Understanding lymphocyte subpopulations is crucial for diagnosing and managing these conditions.

    Purpose of the Study:

    • To compare lymphocyte subpopulations in patients with PBC, CAH, and healthy controls.
    • To investigate the relationship between lymphocyte changes and immune function in PBC.

    Main Methods:

    • Peripheral blood samples were collected from 13 PBC patients, 13 CAH patients, and 16 healthy controls.
    • Lymphocyte subpopulations, including activated T cells and K cells, were quantified.
    • Lymphocyte-mediated antibody-dependent cytotoxicity was assessed.

    Main Results:

    • Patients with PBC exhibited a significant reduction in both relative and absolute counts of activated T cells and K cells compared to normal subjects.
    • No significant reduction in these lymphocyte subpopulations was observed in CAH patients.
    • The decrease in K cells in PBC patients correlated with diminished lymphocyte-mediated antibody-dependent cytotoxicity.

    Conclusions:

    • Primary biliary cirrhosis is associated with specific deficits in activated T cells and K cells.
    • These immune alterations in PBC may contribute to impaired antibody-dependent cytotoxicity.
    • The findings differentiate the immunologic profiles of PBC and CAH.

    More Related Videos

    Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells06:55

    Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

    Published on: February 22, 2020

    19.7K
    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    4.0K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...